UBC and CDRD spinout Sitka Biopharma has now lured $5.5m in total and is readying its bladder cancer treatment for initial clinical trials.

Sitka Biopharma, a Canada-based bladder cancer treatment technology spun out of University of British Columbia and life sciences commercialisation agency Centre for Drug Research and Development (CDRD), has secured $1.2m from CDRD.
Founded in 2013, Sitka Biopharma is working on cancer drugs that utilise nanoparticle technology to improve absorption in difficult-to-penetrate tissues.
The company’s prime commercialisation candidate, STK-01, is initially indicated for bladder cancer but could also have applications in ovarian cancer and other diseases.
CDRD’s investment…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?